Dergiler / Turkish Journal of Gastroenterology / 2020 / Cilt: 31 - Sayı: 12

Berberine inhibits liver damage in rats with non-alcoholic fatty liver disease by regulating TLR4/MyD88/NF-κB pathway

Sayfa
902–909
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

BBR could also reverse the nuclear translocation of NF-κB in the primary liver cells.Conclusion: BBR alleviated the progress of NAFLD and liver damage, which might contribute to inhibit the nuclear translocation of NFκB via the TLR4/MyD88/NF-κB pathway.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Background/Aims: This study aimed to explore the therapeutic effects and underlying mechanism of berberine (BBR) on the non-alcoholic fatty liver disease (NAFLD) induced by high-fat diet (HFD).Materials and Methods: Rats were randomly divided into the following 4 groups: control (normal diet), model (HFD), polyene phosphatidylcholine HFD+PPC, and BBR (HFD+BBR) group.
📊
Temel Bulgular & Veri:The NAFLD models were prepared by feeding with HFD for 12 weeks.
💡
Sonuç & Katkı:BBR could also reverse the nuclear translocation of NF-κB in the primary liver cells.Conclusion: BBR alleviated the progress of NAFLD and liver damage, which might contribute to inhibit the nuclear translocation of NFκB via the TLR4/MyD88/NF-κB pathway.
🔬Tür:Modelleme & Sayısal Simülasyon
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Background/Aims: This study aimed to explore the therapeutic effects and underlying mechanism of berberine (BBR) on the non-alcoholic fatty liver disease (NAFLD) induced by high-fat diet (HFD).Materials and Methods: Rats were randomly divided into the following 4 groups: control (normal diet), model (HFD), polyene phosphatidylcholine HFD+PPC, and BBR (HFD+BBR) group. The NAFLD models were prepared by feeding with HFD for 12 weeks. The liver tissues were observed by oil red O staining. H&E staining was used to detect pathological changes in the liver tissues. Serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) were detected by an automatic biochemical analyzer. ELISA was performed to observe the inflammatory cytokines (TNF-α, IL-6, and IL-1β) expressions. The levels of TLR4, MyD88, and NF-κB p65 were analyzed using western blot and qRT-PCR, respectively. The nuclear translocation levels of NF-κB in the primary liver cells were measured using flow cytometry.Results: BBR could significantly alleviate the liver tissue steatosis and inflammatory cell infiltration; reduce the NAFLD activity scores and serum levels of ALT, AST, TC, and LDL-C; decrease the levels of TNF-α, IL-6, and IL-1β, and reduce the expression of TLR4, MyD88, and NF-κB in the liver tissues. BBR could also reverse the nuclear translocation of NF-κB in the primary liver cells.Conclusion: BBR alleviated the progress of NAFLD and liver damage, which might contribute to inhibit the nuclear translocation of NFκB via the TLR4/MyD88/NF-κB pathway.

🔖

Bu Makaleye Atıf Yap

WANG, L., JIA, Z., WANG, B., ZHANG, B. (2020). Berberine inhibits liver damage in rats with non-alcoholic fatty liver disease by regulating TLR4/MyD88/NF-κB pathway. Turkish Journal of Gastroenterology, Cilt: 31 - Sayı: 12, 902–909. https://ajindex.com/articles/408684

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (14)

  1. Tomasiewicz K, Flisiak R, Halota W, et al. Recommendations for the management of non-alcoholic fatty liver disease (NAFLD). Clin Exp Hepatol 2018; 4: 153-7
  2. Koch LK, Yeh MM. Nonalcoholic fatty liver disease (NAFLD): Diag nosis, pitfalls, and staging. ANN DIAGN PATHOL 2018; 37: 83-90
  3. Younossi ZM. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Implications for liver transplantation. Liver Transpl 2018; 24: 166-70
  4. Snyder HS, Sakaan SA, March KL, et al. Non-alcoholic Fatty Liver Disease: A Review of Anti-diabetic Pharmacologic Therapies. J Clin Transl Hepatol 2018; 6: 168-74
  5. Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64: 73-84
  6. Gastaldelli A. Insulin resistance and reduced metabolic flexibility: cause or consequence of NAFLD? Clin Sci (Lond) 2017; 131: 2701-4
  7. Assuncao S, Sorte N, Alves C, et al. Inflammatory cytokines and non-alcoholic fatty liver disease (NAFLD) in obese children and ado lescents. Nutr Hosp 2018; 35: 78-83
  8. Zhou Y, Ding YL, Zhang JL, et al. Alpinetin improved high fat di et-induced non-alcoholic fatty liver disease (NAFLD) through im proving oxidative stress, inflammatory response and lipid metabo lism. Biomed Pharmacother 2018; 97: 1397-408
  9. Gouni-Berthold I, Papanas N, Maltezos E. The role of oral antidia betic agents and incretin mimetics in type 2 diabetic patients with non-alcoholic fatty liver disease. Curr Pharm Des 2014; 20: 3705-15
  10. Zhang Y, Li X, Zhang Q, et al. Berberine hydrochloride prevents postsurgery intestinal adhesion and inflammation in rats. J Pharma col Exp Ther 2014; 349: 417-26
  11. Li YJ, Hu XB, Lu XL, et al. Nanoemulsion-based delivery system for enhanced oral bioavailability and caco-2 cell monolayers per meability of berberine hydrochloride. Drug Deliv 2017; 24: 1868-73
  12. Feng WW, Kuang SY, Tu C, et al. Natural products berberine and curcumin exhibited better ameliorative effects on rats with non-al cohol fatty liver disease than lovastatin. Biomed Pharmacother 2018; 99: 325-33
  13. Zhao L, Cang Z, Sun H, et al. Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease. BMC Endocr Disord 2017; 17: 13
  14. Wang X, Feng S, Ding N, et al. Anti-Inflammatory Effects of Ber berine Hydrochloride in an LPS-Induced Murine Model of Mastitis. Evid Based Complement Alternat Med 2018; 2018: 5164314